Date & Time: March 16, 2022 | 7:00 am PT
Presenters: Dr. Werner Schroth and Dr. Alexander Sartori
Sponsored by Agena Bioscience®Watch Video Recording
Identifying PIK3CA variants provides a reliable tool for screening clinically relevant mutations in breast cancer tumors.
Leading experts, Dr. Werner Schroth and Dr. Alexander Sartori, will discuss PIK3CA profiling using tumor biopsy specimens and highly sensitive analysis methods that provide accurate and reliable information for clinical trial evaluation and breast cancer management research.
Dr. Werner Schroth and Dr. Alexander Sartori will be available to answer questions.
The MassARRAY® System is a proven platform which integrates the best of mass spectroscopy and multiplex PCR; providing a unique combination of sensitivity, cost effectiveness, fast turnaround time, ease of use, and flexibility. These benefits strongly address the needs of clinicians to apply patient specific genomic information to make personalized treatment and monitoring decisions.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Germany
Dr. Werner Schroth is a scientist in oncology research ‘pharmacogenomics and molecular profiling of breast cancer’, Institute of Clinical Pharmacology, at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen. Dr. Schroth received his PhD from the J.W.Goethe University, Frankfurt, Germany and completed post-doctoral studies at ITZ Hannover, Germany. He continued his career as a consultant and scientist-in-charge of Autoimmune Diagnostics at the Dermatological Institute, Offenbach, Germany. In his current work, Dr. Schroth focuses on pharmacogenomics of breast cancer including mitigating clinical resistance of hormone-receptor positive breast cancer treatment and the molecular profiling of breast tumors based on their transcriptome and somatic mutation landscape.
Scientific Affairs, Agena Bioscience
Dr. Alexander Sartori is a chemist with a PhD from the University of Kiel in cell biology; Alexander has 20 years’ experience in the life science industry and broad technical and application skills with a focus on oncology. For the past 10 years he has managed various collaborations and international consortia. In 2015 Alexander joined Agena Bioscience and in his current position he leads Agena’s Scientific Affairs oncology activities globally with a focus on liquid biopsy.Watch Video Recording